The increase in Q3 2023 was also attributable to increases in product candidate manufacturing expenses, increases in research studies and increases in payroll and compensation expenses. We recorded a net loss of approximately $3.2 million for the third quarter of 2023 or $0.29 per share compared to a net loss of approximately $2.3 million or $0.21 per share for the third quarter of 2022. Our loss from operations in the third quarter of 2023 was partially offset by interest income and other income net, totaling approximately $362,000. Our interest income and other income net increased by an aggregate of approximately $482,000 for the third quarter of 2023 compared to the third quarter of 2022. This increase was attributable to an increase in interest of approximately $194,000 increases in dividend income of approximately $152,000 and an increase in unrealized gains on investments of approximately $102,000.
As of September 30, 2023, we had approximately 10.87 million shares of common stock outstanding, outstanding warrants to purchase approximately 177,998 shares and outstanding options to purchase approximately 1.1 million shares. These warrants and options, combined with our outstanding shares of common stock, give us a total fully diluted shares outstanding of approximately 12.1 million shares as of September 30, 2023. Our cash position, which includes cash equivalents and marketable securities was approximately $44.9 million as of September 30, 2023. We anticipate this balance will provide us with a cash runway into at least Q3 of 2025. Importantly, we believe our solid financial position will fuel continued growth and evolution of our RADR AI platform, accelerate the development of our portfolio of targeted oncology drug candidates and allow us to introduce additional targeted programs and collaboration opportunities in a capital-efficient manner.
Our team continues to be very productive under a hybrid operating model. This hybrid model also removes geographic restrictions to our hiring initiatives, which has given us the ability to recruit extremely high-caliber team members that otherwise might not be available. We currently have 21 employees focused primarily on leading and advancing our research and drug development efforts. We see this number expanding slightly in coming quarters as we add additional experienced and talented individuals to help advance our mission. I’ll now turn the call back over to Panna for an update on some of our development programs. Panna?
Panna Sharma: Thank you, David. This past quarter, we launched another first-in-human Phase I program with LP-284, a novel synthetically lethal small-molecule in refractory non-Hodgkin’s lymphomas and sarcomas where there is a significant patient need for improved therapies. As I mentioned on our second quarter call, we had planned to launch this trial here in Q4, and that’s our current, we’re on track to do that. So we’ve launched both 184 and 284, 1 quarter after another, which is what we had talked about earlier this year. Now 284 can work effectively both as monotherapy or in combination with other standard of care agents. But finding needs are as critically needed and important in cancer and can oftentimes take months or years of lab work.
But computational approaches are increasing their ability to predict meaningful and clinically relevant combination regimens for cancer. And our team continues to increase the value of our platform in this regard, and it helps us sharpen the focus of our existing clinical drug candidates to very specific populations. With 284, we were able to understand that advanced non-Hodgkin’s lymphoma cancer subtypes with DNA damage response deficiency, notably those with compromised functioning of the ATM gene, the Ataxia gene, the ATM can cause a tremendous amount of sensitivity to our drug agent. In the U.S., Europe, mantle cell, double hit and other high-grade B cell lymphomas are diagnosed in about 16,000 to 20,000 patients each year and have an estimated annual market potential of $3 billion to $4 billion.
We also saw with this drug candidate that in PDX models of high-grade B cell lymphomas, LP-284 showed synergistic and significantly enhanced anticancer activity when used in combination with rituximab. In in-vivo PDX models, the synergy of rituximab with our drug LP-284 was 63% more effective in destroying high-grade B cell lymphomas than rituximab alone. When we put 284 on rituximab, we had 93% tumor growth inhibition where rituximab alone only had 57%. So as many of you probably know, rituximab is a standard of care approved therapy in a wide range of B cell cancers and non-Hodgkin’s lymphomas. We plan on releasing additional details on this data and on the set of results in the coming month. Nearly all mantle-cell DHL and high-grade cell lymphoma patients relapsed from the current standard of care agent, and we believe there is an urgent and unmet need to introduce this drug either as monotherapy or in combination in the relapsed and refractory setting for this patient group.
Moving on to 184. We discussed that we dosed the first patient in the Phase IA clinical trial. It was the first in human Phase I basket trial across multiple solid tumor indications. We think the market potential for this drug is quite significant since 20% to 25% of solid tumors have DNA damage repair deficiency and the majority of them become refractory to existing standard of care therapies. This trial is anticipated to enroll patients that have relapsed refractory advanced solid tumors, such as pancreatic, GBM, triple-negative breast cancer, lung, multiple other solid tumors, including GBM and brain cancers. Lantern expects to continue Phase I enrollment throughout the remainder of this year with additional sites and patients and potentially finish the first few cohorts of patients and also have a number of major centers like Fox Chase and Johns Hopkins Medicine and USC also joined the trial.
